Source comparison
CJC-1295 No DAC vs CJC-1295 No DAC & Ipamorelin: Direct Comparison
GH Peak Amplitude 2–4× baseline at 100mcg dose 4–12× baseline (combination dose-dependent) Combination produces significantly higher peak GH. Synergy validated in preclinical models Pulse Duration 2–3 hours return to baseline 3–5 hours sustained elevation Ipam
This comparison does not assign a generated winner or score.
- GH Peak Amplitude
- 2–4× baseline at 100mcg dose
- 4–12× baseline (combination dose-dependent)
- Combination produces significantly higher peak GH. Synergy validated in preclinical models
- Pulse Duration
- 2–3 hours return to baseline
- 3–5 hours sustained elevation
- Ipamorelin extends effective release window by suppressing somatostatin rebound
- Dosing Frequency
- Every 3–4 hours for pulsatile effect
- 2–3× daily; Ipamorelin pre-dosed 5–10 minutes before CJC
- Combination requires timing precision but allows fewer total administrations per day
- Receptor Desensitization Risk
- Minimal with proper spacing
- Minimal; dual-pathway activation prevents single-receptor burnout
- Both protocols preserve physiological pulsatility when dosed correctly
- Side Effect Profile
- Transient facial flushing, mild head pressure (5–10% incidence)
- Same as CJC alone; Ipamorelin adds rare transient nausea (<3% incidence)
- Combination does not compound side effects. Ghrelin receptor selectivity avoids cortisol/prolactin elevation
- Cost per 30-Day Protocol
- $120–180 (CJC-1295 no DAC only)
- $200–320 (both peptides)
- 40–60% cost increase for 50–200% GH amplitude gain. Cost-effectiveness depends on research priorities
- The table shows what the mechanism predicts: combination protocols produce higher peak GH levels and longer effective windows, but require more complex dosing coordination and incur higher material costs. The critical question for any research protocol is whether the amplified GH response justifies the added variables. For studies focused on maximum GH peak amplitude. Fat oxidation kinetics, anabolic signaling pathways, or IGF-1 upregulation dynamics. The combination is superior. For studies investigating natural pulsatile GH patterns or receptor pharmacokinetics, CJC-1295 no DAC alone provides cleaner data with fewer confounding variables.
- One underappreciated factor: pituitary reserve capacity. In younger preclinical models with high endogenous GH secretion capacity, CJC-1295 no DAC alone may approach the upper limit of what the pituitary can release in a single pulse. Adding Ipamorelin produces marginal additional benefit. In older models or those with impaired GH axis function, the combination shows the largest differential because Ipamorelin's somatostatin suppression unlocks residual secretory capacity that CJC-1295 no DAC alone cannot fully access. This means the 'better' protocol is age-dependent and baseline-dependent. Not universally fixed.